HCPCS Code J9025: Injection, Azacitidine, 1 mg

HCPCS J9025: Injection of azacitidine, 1 mg for AML, MDS, and related disorders. Includes billing and documentation guidance.

Use Code

## **What is injection of azacitidine?** HCPCS code J9025 represents the injection of azacitidine, 1 mg, a chemotherapy medication primarily used for the treatment of certain myelodysplastic syndromes (MDS), including refractory anemia and refractory anemia with excess blasts. It is also indicated for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) in patients whose disease is not immediately life-threatening but requires intervention. Administered over a few weeks, injection azacitidine 1 mg works to slow abnormal blood cell growth and improve symptoms such as anemia, nausea, and vomiting. Azacitidine, also known as Vidaza, can be given as a subcutaneous injection or intravenous infusion and is often part of a comprehensive treatment plan that may include supportive care to manage thrombocytopenia, neutropenia, and other side effects. Patients receiving this drug require close monitoring to ensure proper dosing, reduce errors, and manage potential complications. Its use is intended for specific indications as outlined in oncology guidelines, and the code is categorized under chemotherapy agents for billing and reimbursement purposes.

## **J9025 documentation requirements** HCPCS code J9025 represents the injection of azacitidine, 1 mg, a chemotherapy medication primarily used for the treatment of certain myelodysplastic syndromes (MDS), including refractory anemia and refractory anemia with excess blasts. It is also indicated for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) in patients whose disease is not immediately life-threatening but requires intervention. Injection azacitidine 1 mg is typically administered over a few weeks in repeated cycles. The drug works by altering the DNA in abnormal cells, helping to slow their growth and allowing the body to produce healthier blood cells. This can help manage symptoms such as anemia, nausea, vomiting, thrombocytopenia, and neutropenia. Treatment often involves close monitoring for side effects and regular blood tests. Depending on the indications, azacitidine may be given with supportive care to improve quality of life and reduce complications from leukemia or MDS.

## **J9025 billing requirements** When billing HCPCS code J9025 for injection azacitidine 1 mg, providers must ensure documentation supports the patient’s diagnosis and medical necessity. Records should include: - Patient diagnosis (e.g., acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndromes, refractory anemia with or without excess blasts) - Dosage and total amount administered in mg - Cycle length and treatment weeks (common regimens run for several weeks) - Route of administration (subcutaneous or intravenous) - Response to treatment and monitoring of symptoms such as anemia, nausea, vomiting, thrombocytopenia, and neutropenia - Any supportive care provided (e.g., antiemetics, blood transfusions) - Physician’s order, signed and dated, matching the billing claim - Accurate documentation helps avoid errors, ensures claims align with intended treatment plans, and supports compliance with payer requirements.

## **Other relevant codes** - J9027 – Injection, clofarabine, 1 mg - 96401 – Chemotherapy administration, subcutaneous or intramuscular, non-hormonal antineoplastic - 96409 – Chemotherapy administration, intravenous, up to 1 hour